Toward better dialysis compatibility: Advances in the biochemistry and pathophysiology of the peritoneal membranes

实现更好的透析相容性:腹膜生物化学和病理生理学的进展

基本信息

  • 批准号:
    13307031
  • 负责人:
  • 金额:
    $ 28.45万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
  • 财政年份:
    2001
  • 资助国家:
    日本
  • 起止时间:
    2001 至 2002
  • 项目状态:
    已结题

项目摘要

Peritoneal solute transport progressively increases with time on PD, enhances the dissipation of the osmotic gradient, and eventually reduces ultrafiltration capacity. Functionally, the changes of the failing peritoneal membrane are best described as an increased functional area of exchange for small solutes between blood and dialysate. Histologically, these events are associated with vascular proliferation and structural changes of pre-existing vessels. Gathered evidence, including informations on the composition of peritoneal cavity fluids and its dependence on the uremic environment, have cast a new light on the molecular mechanisms of decline in peritoneal membrane function. Chronic uremia per se modifies the peritoneal membrane and increases the functional area of exchange for small solutes. Biochemical alterations in the peritoneum inherent to uremia might be, at least in part, accounted for by severe reactive carbonyl compounds overload originating both from uremic circulation and PD fluid ("peritoneal carbonyl, stress"). The molecular events associated with long-term PD are similar but more severe than those present in chronic uremia without PD, including modifications of nitric oxide synthase (NOS) and angiogenic growth factors expression, and advanced glycation and lipoxidation of the peritoneal proteins. Furthermore, the progresses made in the dissection of the molecular events leading to peritoneal membrane failure open new avenues to develop a safe, more biocompatible peritoneal dialysis technologies, i.e., the glyoxalase detoxification system and RCO trapping bead.
腹膜溶质转运随着腹膜透析时间的延长而逐渐增加,增强了渗透梯度的消散,并最终降低了超滤能力。在功能上,失效腹膜的变化最好描述为血液和透析液之间小溶质交换的功能面积增加。在组织学上,这些事件与血管增殖和既存血管的结构变化相关。收集到的证据,包括腹膜腔液体的组成及其对尿毒症环境的依赖性的信息,为腹膜功能下降的分子机制提供了新的线索。慢性尿毒症本身改变了腹膜,增加了交换小分子溶质的功能面积。尿毒症固有的腹膜生化改变可能至少部分是由于尿毒症循环和PD液(“腹膜羰基,应激”)引起的严重反应性羰基化合物过载。与长期PD相关的分子事件与慢性尿毒症无PD患者相似,但更严重,包括一氧化氮合酶(NOS)和血管生成生长因子表达的改变,以及腹膜蛋白的晚期糖基化和脂氧化。此外,在解剖导致腹膜衰竭的分子事件方面取得的进展为开发安全的、更生物相容的腹膜透析技术开辟了新的途径,即,草甘膦酶解毒系统和RCO捕获珠。

项目成果

期刊论文数量(112)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Morimoto K, et al.: "Cytoprotective role of heme oxygenase (HO)-1 in human kidney with various renal diseases"Kidney Int. 60. 1858-1866 (2001)
Morimoto K 等人:“血红素加氧酶 (HO)-1 在患有各种肾脏疾病的人类肾脏中的细胞保护作用”Kidney Int。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Asano M, et al.: "Renal proximal tubular metabolism of protein-linked pentoisidine, an advanced glycation end product"Nephron. 91. 688-694 (2002)
Asano M 等人:“蛋白质连接的戊糖苷的肾近端肾小管代谢,一种晚期糖基化终产物”肾单位。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Miyata T et. al: "Alterations of non-enzymatic biochemistry in uremia, diabetes, and atherosclerosis (《carbonyl stress》)"Bulletin et Memoires de l'Academie royale de Medecine de Belgique. 157. 189-198 (2002)
Miyata T 等人:“尿毒症、糖尿病和动脉粥样硬化中非酶生物化学的改变(《羰基应激》)”Bulletin et Memoires de lAcademie Royale de Medecine de Belgique 157. 189-198 (2002)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Asano M, et al.: "Renal tubular metabolism of protein-linked pentoisidine,an advanced glycation end product"Nephron. (in press).
Asano M 等人:“蛋白连接的戊代乙胺的肾小管代谢,一种高级糖基化终产物”肾单位。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MIYATA Toshio其他文献

New direction of PAI-1 inhibitor development: Clinical application to cancer treatment
PAI-1抑制剂开发新方向:癌症治疗的临床应用
  • DOI:
    10.2491/jjsth.29.487
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    0
  • 作者:
    DAN Takashi;UCHIDA Wataru;HIRATSUKA Hideaki;OSHIMA Yoshiteru;MIYATA Toshio
  • 通讯作者:
    MIYATA Toshio

MIYATA Toshio的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MIYATA Toshio', 18)}}的其他基金

The development of a novel mechanism therapeutic drug for rare intractable inflammatory diseases
罕见难治性炎症疾病新机制治疗药物的研发
  • 批准号:
    24249033
  • 财政年份:
    2012
  • 资助金额:
    $ 28.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Development of novel compounds that enhance HIF activity and ameliorate chronic hypoxia in diabetic nephropathy and other diseases.
开发增强 HIF 活性并改善糖尿病肾病和其他疾病慢性缺氧的新型化合物。
  • 批准号:
    17209030
  • 财政年份:
    2005
  • 资助金额:
    $ 28.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Study on the pathological role of AGEs in renal diseases
AGEs在肾脏疾病中的病理作用研究
  • 批准号:
    09044280
  • 财政年份:
    1997
  • 资助金额:
    $ 28.45万
  • 项目类别:
    Grant-in-Aid for international Scientific Research
QUALITATIVE AND QUANTITATIVE ANALYSIS OF GENES EXPRESSED IN CULTURED HUMAN GLOMERULAR MESANGIAL CELLS.
对培养的人肾小球系膜细胞中表达的基因进行定性和定量分析。
  • 批准号:
    07457240
  • 财政年份:
    1995
  • 资助金额:
    $ 28.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)

相似海外基金

Development of enzymatic tools for rapid measurement of Advanced Glycation End Product-protein adducts
开发用于快速测量高级糖基化终产物-蛋白质加合物的酶工具
  • 批准号:
    10757215
  • 财政年份:
    2023
  • 资助金额:
    $ 28.45万
  • 项目类别:
Noninvasive measurement of advanced glycation end product level to predict the curative effect of diabetic macular edema
无创测量晚期糖基化终末产物水平预测糖尿病黄斑水肿的疗效
  • 批准号:
    15K20252
  • 财政年份:
    2015
  • 资助金额:
    $ 28.45万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Analysis of the disorder on cell function induced by advanced glycation end-product (AGE) in dental pulp, gingival and alveolar bone tissues
晚期糖基化终末产物(AGE)对牙髓、牙龈及牙槽骨组织细胞功能紊乱的分析
  • 批准号:
    15K15701
  • 财政年份:
    2015
  • 资助金额:
    $ 28.45万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Novel therapeutic strategy targeting advanced glycation end product
针对晚期糖基化终产物的新治疗策略
  • 批准号:
    26462662
  • 财政年份:
    2014
  • 资助金额:
    $ 28.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigation of diabetes-associated periodontitis pathogenesis from a point of relevance for advanced glycation end-product and redox regulation.
从与晚期糖基化终产物和氧化还原调节的相关性角度研究糖尿病相关牙周炎的发病机制。
  • 批准号:
    24792333
  • 财政年份:
    2012
  • 资助金额:
    $ 28.45万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumor
高级糖基化终产物 (RAGE) 通路受体在脑肿瘤中的作用
  • 批准号:
    8890797
  • 财政年份:
    2011
  • 资助金额:
    $ 28.45万
  • 项目类别:
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumor
高级糖基化终产物 (RAGE) 通路受体在脑肿瘤中的作用
  • 批准号:
    8507470
  • 财政年份:
    2011
  • 资助金额:
    $ 28.45万
  • 项目类别:
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumors
高级糖基化终产物 (RAGE) 通路受体在脑肿瘤中的作用
  • 批准号:
    9312100
  • 财政年份:
    2011
  • 资助金额:
    $ 28.45万
  • 项目类别:
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumor
高级糖基化终产物 (RAGE) 通路受体在脑肿瘤中的作用
  • 批准号:
    8329598
  • 财政年份:
    2011
  • 资助金额:
    $ 28.45万
  • 项目类别:
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumor
高级糖基化终产物 (RAGE) 通路受体在脑肿瘤中的作用
  • 批准号:
    8707217
  • 财政年份:
    2011
  • 资助金额:
    $ 28.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了